A buy, hold, or sell recommendation issued by a financial analyst at a brokerage or research firm, typically accompanied by a price target based on valuation models.
Sell-side analysts employed by investment banks and brokerage firms conduct detailed research on individual companies and publish reports with ratings (Buy/Overweight, Hold/Neutral, Sell/Underweight) and 12-month price targets. Analysts model company financials, build discounted cash flow (DCF) and comparable-company valuation models, attend earnings calls, meet management, and synthesise industry data into investment recommendations.
The statistical reality is that analyst ratings skew heavily bullish: buy recommendations typically outnumber sells by 4:1 or more, partly due to investment banking conflicts of interest (firms rate companies whose equity and debt issuance they underwrite), partly because negative research relationships strain management access. Sell recommendations are rare and can provoke management to cut off access.
Despite these biases, analyst rating changes and target revisions move stocks - particularly in the first few hours after publication. An upgrade from Neutral to Buy by a well-regarded analyst at a major bank can add 3–8% to a stock intraday. Downgrades, especially from Buy to Sell (rare), can produce 5–15% declines. The most actionable analyst signals are consensus estimate revisions - when multiple analysts simultaneously raise EPS estimates for the same company, it often precedes sustained price outperformance.
For active traders, analyst consensus data (average rating, number of bulls vs bears, average price target vs current price) provides a sentiment snapshot. Stocks with a high percentage of sell-side buy ratings and a wide premium between the price target and market price may already have bullish sentiment priced in - reducing the catalyst for further upside.
Worked Example
A pharmaceutical company announces Phase 3 trial success for a cancer drug. Three analysts upgrade from Neutral to Buy within 24 hours, setting price targets of USD 95–110 versus the prior USD 68 market price. The consensus target-to-price ratio jumps to 1.42× (42% implied upside). The stock rises 15% on upgrade day. Traders monitoring consensus revisions use this as a momentum signal - when multiple analysts simultaneously raise estimates after a positive catalyst, the sustained institutional buying required to adjust their model portfolios supports price over the following weeks.